Literature DB >> 24517956

Treatment of Small Cell Carcinoma of the Bladder With Chemotherapy and Radiation after Transurethral Resection of a Bladder Tumor.

Curtis M Bryant1, Long H Dang, Bruce K Stechmiller, Scott M Gilbert, Christopher G Morris, Robert A Zlotecki.   

Abstract

OBJECTIVES: Small cell carcinoma of the bladder is a rare, aggressive cancer with a high potential for metastases. We analyzed outcomes of patients with small cell carcinoma of the bladder treated curatively with chemotherapy and radiotherapy with bladder preservation.
MATERIALS AND METHODS: We reviewed the medical records of 11 patients treated with radiotherapy at our institution between 1988 and 2010 for biopsy-proven small cell carcinoma of the bladder clinically localized to the true pelvis. Each patient received transurethral resection of the bladder tumor followed by induction chemotherapy and consolidative radiation or concurrent chemoradiation. After completing radiotherapy, cystoscopy was performed to evaluate local response. Overall survival, distant metastasis-free survival, local-regional control, and complete response rates are reported.
RESULTS: The median follow-up was 1.1 years for all patients and 10 years for survivors. Nine patients had clinical T3-T4 disease and 3 had node-positive disease. All patients were treated with conventional radiotherapy (median dose, 59 Gy) and cisplatin-based chemotherapy. Eight patients had a cystoscopy after completing chemoradiation, all of whom had a biopsy-proven complete response. The remaining 3 patients developed a distant metastasis before cystoscopy could be performed. The 3-year overall survival rate was 24%; the distant metastasis-free survival rate was 27%; and the local-regional control rate was 78%. All patients who achieved local control maintained functioning bladders. No Common Terminology Criteria for Adverse Events toxicity scale, version 3.0 late grade 3 genitourinary or gastrointestinal toxicities occurred.
CONCLUSIONS: Primary chemoradiation provides reasonable local-regional control rates with a functioning bladder, even for patients with locally advanced disease, and is an effective alternative to cystectomy when aiming for bladder conservation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 24517956     DOI: 10.1097/COC.0000000000000027

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  6 in total

1.  Novel scoring system guiding the incorporation of adjuvant RT for neuroendocrine neoplasms treated with surgical resection followed by chemotherapy.

Authors:  Jeanny Kwon; Byoung Hyuck Kim
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-17       Impact factor: 4.322

2.  Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases.

Authors:  Gang Wang; Li Xiao; Miao Zhang; Ashish M Kamat; Arlene Siefker-Radtke; Colin P Dinney; Bogdan Czerniak; Charles C Guo
Journal:  Hum Pathol       Date:  2018-05-12       Impact factor: 3.466

Review 3.  Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up.

Authors:  Yanling Wang; Qijun Li; Jing Wang; Mengting Tong; Haibo Xing; Yanan Xue; Hongming Pan; Changxing Huang; Da Li
Journal:  Med Oncol       Date:  2019-10-29       Impact factor: 3.064

Review 4.  Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease?

Authors:  Yvonne Klaile; Katrin Schlack; Martin Boegemann; Julie Steinestel; Andres Jan Schrader; Laura-Maria Krabbe
Journal:  Transl Androl Urol       Date:  2016-10

5.  Radiation Therapy as Definitive Local Treatment in Patients with Limited-Stage Small Cell Carcinoma of the Bladder: Does total dose matter?

Authors:  Elizabeth Germino; Benjamin W Fischer-Valuck; Soumon Rudra; Yuan James Rao; Jessika Contreras; Christopher Abraham; Jeff Michalski; Hiram Gay
Journal:  Bladder Cancer       Date:  2018-07-30

6.  Small Cell Cancer of the Bladder and Prostate: A Retrospective Review from a Tertiary Cancer Center.

Authors:  Shahida Ahmed; Sam Neufeld; Tadeusz J Kroczak; Bashir Bashir; Naseer Ahmed; Piotr Czaykowski; Ibrahim Aljada; Rashmi Koul; Katie Galloway; Darrel E Drachenberg
Journal:  Cureus       Date:  2015-08-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.